ArticleJournal of hepatocellular carcinoma2026
Preoperative Prediction of TACE Refractoriness in Hepatocellular Carcinoma Using CT-Based Radiomics Model.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop an integrated predictive model that combines radiomics, and clinical risk factors to predict early refractoriness to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Methods: The study cohort comprised 180 HCC patients from Hospital A, while the external validation cohort included 42 patients from Hospital B. Optimal radiomic features extracted from computed tomography (CT) were selected using both LASSO regression and the Boruta algorithm. Eight machine learning models based on radiomics were developed. SHapley Additive Explanations (SHAP) were utilized to interpret the predictions and assess feature importance of the best model. Furthermore, independent clinical risk factors for TACE refractoriness were identified within the study cohort, leading to the construction of a combined model. The predictive performance of the model was evaluated using the area under the curve (AUC), calibration curve, and decision-curve analysis (DCA). Results: The random forest (RF) model exhibited the superior performance, achieving an AUC of 0.841 (95% CI: 0.731-0.950) and 0.777 (95% CI: 0.624-0.929) in the testing and validation cohorts, respectively. SHAP analysis indicated that radiomic features significantly contributed to the RF model. Subsequently, Radscore was integrated with the clinically independent risk factor (tumor diameter) identified through univariate and multivariate logistic regression to develop the combined model. The combined model exhibited superior AUC performance compared with the clinic and radiomics models, with AUCs of 0.842 (95% CI: 0.736-0.948) and 0.847 (95% CI: 0.721-0.973) in the testing and validation cohorts, respectively. Calibration curve and decision curve analyses confirmed the utility of the combined model nomogram in clinical practice. Conclusion: The combined model exhibits strong predictive performance for early TACE refractoriness, potentially offering improved guidance for decision-making regarding subsequent TACE treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.